Navigation Links
First Patient Enrolled in Cogentus Pharmaceuticals' Pivotal Phase 3 Trial of Novel Combination Medicine
Date:1/15/2008

Worldwide COGENT-1 Clinical Study of CGT-2168 Begins; Focus on Reducing GI

Side Effects of Antiplatelet Therapy

MENLO PARK, Calif., Jan. 15 /PRNewswire/ -- Cogentus Pharmaceuticals, Inc. today announced that the first patient has been enrolled in the company's pivotal Phase 3 study of its novel combination medicine CGT-2168. The patient entered the study at the Mobile Heart Specialists P.C. in Mobile, Ala.

(Logo: http://www.newscom.com/cgi-bin/prnh/20071112/COGENTUSLOGO )

The study will evaluate the antiplatelet medicine CGT-2168, which is a combination of clopidogrel (currently marketed by Bristol-Myers Squibb Co. and Sanofi-Aventis as Plavix(R)) and a gastroprotectant (omeprazole) in a single pill. Developed by Cogentus, CGT-2168 is designed to provide protective cardiovascular benefits while reducing potentially serious gastrointestinal side effects commonly associated with dual antiplatelet therapy.

"This is an important milestone for Cogentus that holds promise for the millions of patients who are prescribed dual antiplatelet treatment," said Cogentus Chairman and Chief Executive Officer Mark A. Goldsmith, M.D., Ph.D. "We believe CGT-2168 has the potential to reduce significantly the gastrointestinal side effects that can cause patients to interrupt their treatment and further compromise their health status."

Antiplatelet therapy is an integral part of treating patients with acute coronary syndrome and has been shown to be effective in preventing major cardiovascular events. However, the combination of clopidogrel and aspirin is associated with gastrointestinal bleeding, which in some cases requires hospitalization and can even result in death.

The global trial is known as COGENT-1 (Clopidogrel and the Optimization of Gastrointestinal Events Trials) and is part of a clinical program expected to enroll more tha
'/>"/>

SOURCE Cogentus Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
3. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
4. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
5. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
6. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
7. Tainted Chinese Food Ingredients First Discovered in 2005
8. First Patient Enrolled in Europe in Ovature Phase III Ovarian Cancer Trial
9. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
10. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
11. Opko Health Doses First Patient in Phase 3 COBALT Trial of Bevasiranib for the Treatment of AMD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2015)... Ga., April 27, 2015  MiMedx Group, Inc. ... company utilizing human amniotic tissue and patent-protected processes ... for the Wound Care, Surgical, Orthopedic, Spine, Sports ... today its record results for the first quarter ... announced today the decision of its Board of ...
(Date:4/27/2015)... 2015  Consumer Watchdog today applauded a California ... prescribers to check a state database before prescribing ... other opioids – to help prevent prescription drug ... SB 482, authored by Sen. Ricardo Lara ... require prescribers to check Controlled Substance Utilization Review ...
(Date:4/27/2015)... , April 27, 2015   Intarcia Therapeutics, ... million synthetic royalty financing with an equity conversion option ... use these funds to accelerate the initiation of additional ... leading oral and injectable type 2 diabetes therapies. In ... infrastructure and talent required to launch ITCA 650 in ...
Breaking Medicine Technology:MiMedx Announces Record Results for First Quarter of 2015 and raises full-year guidance 2MiMedx Announces Record Results for First Quarter of 2015 and raises full-year guidance 3MiMedx Announces Record Results for First Quarter of 2015 and raises full-year guidance 4MiMedx Announces Record Results for First Quarter of 2015 and raises full-year guidance 5MiMedx Announces Record Results for First Quarter of 2015 and raises full-year guidance 6MiMedx Announces Record Results for First Quarter of 2015 and raises full-year guidance 7MiMedx Announces Record Results for First Quarter of 2015 and raises full-year guidance 8MiMedx Announces Record Results for First Quarter of 2015 and raises full-year guidance 9MiMedx Announces Record Results for First Quarter of 2015 and raises full-year guidance 10MiMedx Announces Record Results for First Quarter of 2015 and raises full-year guidance 11MiMedx Announces Record Results for First Quarter of 2015 and raises full-year guidance 12MiMedx Announces Record Results for First Quarter of 2015 and raises full-year guidance 13MiMedx Announces Record Results for First Quarter of 2015 and raises full-year guidance 14Consumer Watchdog Praises Passage of Bill that Requires Physicians Check Prescription Drug Database Before Prescribing Powerful, Addictive Medications 2Consumer Watchdog Praises Passage of Bill that Requires Physicians Check Prescription Drug Database Before Prescribing Powerful, Addictive Medications 3Intarcia Therapeutics Closes Novel $225 Million Synthetic Royalty Financing With Equity Conversion Option At $5.5 Billion Valuation 2Intarcia Therapeutics Closes Novel $225 Million Synthetic Royalty Financing With Equity Conversion Option At $5.5 Billion Valuation 3
... TEL AVIV, Israel, November 30 ... microphone, the most advanced,optical microphone available for use in ... The third generation FOMRI represents a major step ... quality ever, with,low-latency adaptive noise cancelling. The FOMRI-III also ...
... , NEW YORK, Nov. 30 ... company and leading developer of oncology compounds directed to ... Texas M.D. Anderson Cancer Center (Houston, TX) and Stemline ... this collaboration, M.D. Anderson has joined an ongoing Phase ...
Cached Medicine Technology:New Generation Noise Cancelling Optical Microphone Paves Way for Advanced Brain and Speech Research 2Stemline Therapeutics Expands Clinical Oncology Program Directed at Cancer Stem Cells With Addition of M.D. Anderson Cancer Center 2
(Date:4/27/2015)... A new type of festival is emerging in ... Tap at the Science Museum of Virginia not only fills ... hops for a bold, new flavor. , The 21+ festival ... the science behind these frothy beverages. Guests uncover the brewing ... the ingredients that go into beer with Original Gravity and ...
(Date:4/27/2015)... April 27, 2015 A variety of events ... people trapped in substance abuse. Programming for Jericho for boys ... girls, is launching this summer. , The first event is ... to serve adolescents. The Youth Town Jim Jackson Golf Classic ... Monday, May 4, with tee times at 8 a.m. and ...
(Date:4/27/2015)... (PRWEB) April 27, 2015 Moreno Ranches, ... http://www.morenoranches.com/ , is proud to announce their "This is ... interested in Brahman cattle breeding and education was a ... Florida, on April 18, 2015. It brought together ... future interest in cattle breeding in general, and Brahman ...
(Date:4/27/2015)... April 27, 2015 Jesse L. Goodman, ... United States Pharmacopeial Convention (USP) at the recently concluded ... of Medicine at Georgetown University and the Director of ... (COMPASS). , As USP President, a volunteer position, Dr. ... He will be a voting member, ex officio, of ...
(Date:4/27/2015)... "Understanding Mental Disorders: Your Guide to the ... Psychiatric Publishing, a division of the American Psychiatric Association. ... National Press Club in Washington, D.C.. The launch event ... President Paul Summergrad, MD. Guest speakers will include Former ... the book; Paul Gionfriddo, President and CEO of Mental ...
Breaking Medicine News(10 mins):Health News:Science on Tap at the Science Museum of Virginia 2Health News:Golf, Sermon on the Mount and More to Support Youth Town’s Jericho and Eden Programs 2Health News:Leading Ranch for Brahman Cattle for Sale, Moreno Ranches, Announces Conclusion of 'This is It' Event for Brahman Juniors. 2Health News:Dr. Jesse Goodman Elected President of the USP Convention 2Health News:American Psychiatric Association, Patrick Kennedy To Debut New Consumer Guidebook “Understanding Mental Disorders” 2
... of these infant medicines, not product safety, is ... the voluntary withdrawal,- This withdrawal does not affect cough and cold medicines for children ... ... for infants and,children will occur at the October 18 and 19 FDA advisory committee ...
... Oct. 11 Businesses can no longer afford ... spend more than,75 billion dollars on obesity-attributable health ... are lost to obesity-related illness each,year(2). Other costs ... and high turnover rates. Today, business leaders, ...
... * concentrated Tylenol(R) Infants, Drops Plus Cold and ... * PediaCare(R) Infant Drops ... division of McNeil-PPC, Inc., announced today that the,company is voluntarily withdrawing ... directed, these medicines are generally,recognized as safe and effective. While most ...
... and Multimedia Healthcare Communication, PARIS, October 11 ... today two key acquisitions designed to reinforce its ... acquisitions,aim at strengthening Publicis Groupe,s leadership in both ... (Salerno), a highly innovative agency, specialized in,digital communications ...
... Has,a Story," a grassroots and integrated media project celebrating babies ... to survive and thrive --,has been launched by the March ... over the country tell,a special story about the baby they ... March of Dimes. "Families can also express their,hopes and dreams ...
... SACRAMENTO, Calif., Oct. 10 The governor ... (CSU) retirees to,participate in a self-funded comprehensive vision ... the Legislature and governor have recognized,the need to ... said,Barbara LaPlante, President of CSEA Retirees, Inc. "When ...
Cached Medicine News:Health News:Makers of OTC Cough and Cold Medicines Announce Voluntary Withdrawal of Oral Infant Medicines 2Health News:Makers of OTC Cough and Cold Medicines Announce Voluntary Withdrawal of Oral Infant Medicines 3Health News:Experts Urge Businesses to 'Get Real' About Obesity Impact 2Health News:Experts Urge Businesses to 'Get Real' About Obesity Impact 3Health News:Experts Urge Businesses to 'Get Real' About Obesity Impact 4Health News:McNeil Consumer Healthcare is Voluntarily Withdrawing Infants' Cough and Cold Products: 2Health News:McNeil Consumer Healthcare is Voluntarily Withdrawing Infants' Cough and Cold Products: 3Health News:Publicis Groupe Strengthens its Leadership in Digital and Integrated Healthcare Communications in Italy 2Health News:Publicis Groupe Strengthens its Leadership in Digital and Integrated Healthcare Communications in Italy 3Health News:Publicis Groupe Strengthens its Leadership in Digital and Integrated Healthcare Communications in Italy 4Health News:'Every Baby Has a Story' Campaign Tours the Nation for March of Dimes 2Health News:Governor Signs Bill Providing Vision Care Program for State University Retirees 2
PremierEdge™ Slit Knives....
Interchangeable design allows you to select a single handpiece and change tips during the procedure. Universal connector. Disassembles for easy cleaning. Tips can rotate 360 degrees to re-orient port...
Interchangeable design allows you to select a single handpiece and change tips during the procedure. Universal connector. Disassembles for easy cleaning. Tips can rotate 360 degrees to re-orient port...
Interchangeable design allows you to select a single handpiece and change tips during the procedure. Universal connector. Disassembles for easy cleaning. Tips can rotate 360 degrees to re-orient port...
Medicine Products: